Alliança Saúde announces the acquisition of Grupo Meddi and consolidates its leadership in the Northeast.
The R$252 million operation expands the company's presence in Bahia and strengthens its growth strategy focused on synergies and low leverage.
247 - Alliança Saúde e Participações SA (B3: AALR3) announced to the market this Monday (14) the signing of contracts with the partners of Grupo Meddi, sealing the acquisition of 100% of the share capital of 18 companies that make up the Bahia-based group. The information was released through a Relevant Fact published on the company's website.
Meddi Group is considered the largest private and independent diagnostic medicine operator in Northeast Brazil. With over four decades of experience, it currently has 96 service units distributed across 32 cities in Bahia — including diagnostic imaging clinics, clinical analysis laboratories, and collection points in hospitals — covering an estimated population of over 12 million people. In the last 12 months, the group recorded an approximate Gross Revenue of R$ 250 million, standing out for its high profitability and low leverage.
Operation structure and transaction value - The total value of the transaction is R$ 252 million, with a significant portion paid in Alliança's own shares, within a merger model. The exchange ratio will be determined based on the volume-weighted average of the shares in the 60 trading sessions prior to the closing date, limited to a price range that represents a fair value for both parties. The remaining amount will be paid over five years, according to the terms established in the contract.
According to the statement, the shares delivered to the sellers will be subject to a trading restriction period (“lock-up”), in accordance with contractually defined terms. The company highlighted that the structure of the transaction demonstrates mutual trust between the parties and strategic alignment around the potential for appreciation of Alliança.
Strategic expansion and strengthening of operations - The acquisition of Grupo Meddi is part of Alliança's disciplined growth strategy, which prioritizes assets with high profitability, strong reach, and potential for operational synergies. The low debt of the Bahia-based group will also contribute to reducing Alliança's consolidated leverage, strengthening its financial balance sheet.
With the completion of this operation — added to the previously announced acquisition of the São Paulo units of the Cura Group and the expansion of the Public-Private Partnership with the State of Bahia — the company anticipates an increase of R$ 500 million in its Gross Operating Revenue. This move positions Alliança as the largest diagnostic medicine operator in the Northeast, while significantly expanding the share of clinical analyses in its total revenue.
Next steps and pending approvals - The completion of the transaction is still subject to the fulfillment of usual precedent conditions in processes of this type. These include the corporate reorganization of the Meddi Group companies and their holding companies, the approval of the merger at an extraordinary general meeting of Alliança, and the approval of the Administrative Council for Economic Defense (CADE).
The company informed that it will keep the market and its shareholders updated on the progress of the transaction and the convening of the Extraordinary General Meeting (EGM) that will deliberate on the merger.
